CervoMed To Present Key Aspects Of Neflamapimod Clinical Program At 2026 Lewy Body Dementia Association Annual Meeting, Including Updates On Clinical Findings, Global Regulatory Alignment, And Finalized Phase 3 Trial Design In DLB

Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design

Additional data from MRI analyses will also be featured at 2026 American Academy of Neurology Annual Meeting later this month; findings demonstrate neflamapimod's potential positive impact on basal forebrain atrophy and functional connectivity

Dementia with Lewy bodies (DLB) is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union

BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, will present key aspects of its neflamapimod clinical program today at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, GA, including updates on the program's clinical findings, global regulatory alignment, and finalized Phase 3 trial design in DLB.